Patent US4861760A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4861760A Expired / Lapsed US ⏱️ 0.0 years remaining

Ophthalmological composition of the type which undergoes liquid-gel phase transition

Assignee: CHIBRET INTERNATIONAL SA
•
Filing: 1986-09-25
•
Granted: 1989-08-29
•
Expires: 2006-09-25
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The present invention relates to a pharmaceutical composition intended for contacting with a physiological liquid characterized in that said composition is intended to be administered as a non-gelled liquid form and is intended to gel in situ, this composition containing at least one polysaccharide in aqueous solution, of the type which undergoes liquid-gel phase transition gelling in situ under the effect of an increase in the ionic strength of said physiological liquid.

Inventors

  • 👤 Claude Mazuel
  • 👤 Marie-Claire Friteyre

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-08 05:26
CPC Classifications
A; A61; A61K; A61K9/00; C; C12; C12P; C12P19/00; C12P19/04; A61K47/00; A61K47/30; A61K47/36; A61K9/0012; A61K9/0048

Claims Analysis

Total Claims: 9
Claim 1
Independent Claim 38 words
A liquid aqueous ophthalmological composition comprising 0.1 to 2% by weight of gellan gum which on administration to the eye changes from a liquid to a gel as a result of the ionic strength of the lacrimal fluid.
Claim 2
Dependent Claim 38 words
A liquid aqueous ophthalmological composition comprising 0.1 to 2% by weight of gellan gum which on administration to the eye changes from a liquid to a gel as a result of the ionic strength of the lacrimal fluid.
Claim 3
Dependent Claim 19 words
The composition of claim 2 which additionally comprises about 0.001% to 5% by weight of an ophthalmic pharmaceutically-active substance.
Claim 4
Dependent Claim 23 words
The composition of claim 2 wherein the pharmaceutically-active substance is selected from the group consisting of an antibacterial substance and an anti-glaucoma drug.
Claim 5
Dependent Claim 23 words
The composition of claim 3 wherein the antibacterial substance is norfloxacin and the antiglaucoma drug is timolol maleate or a carbonic anhydrase inhibitor.
Claim 6
Dependent Claim 11 words
The composition of claim 1 wherein the gellan gum is Gelrite.
Claim 7
Dependent Claim 19 words
The composition of claim 5 which additionally comprises about 0.001% to 5% by weight of an ophthalmic pharmaceutically-active substance.
Claim 8
Dependent Claim 23 words
The composition of claim 6 wherein the pharmaceutically-active substance is selected from the group consisting of an antibacterial substance and an antiglaucoma drug.
Claim 9
Dependent Claim 29 words
The composition of claim 7 wherein the antibacterial substance is norfloxacin and the antiglaucoma drug is selected from the group consisting of timolol maleate and a carbonic anhydrase inhibitor.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1992-08-28 1993-02-27 1993-08-29 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1996-08-28 1997-02-27 1997-08-29 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2000-08-28 2001-02-27 2001-08-29 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag